Molbio Diagnostics Limited saw a significant shift in its institutional ownership as Kotak Mahindra Mutual Fund crossed the 5% shareholding threshold. The asset management company acquired 570,000 equity shares through open market transactions on October 8, 2026.

This acquisition increased Kotak Mahindra Mutual Fund's total holding in the diagnostics company to 6,319,083 shares, representing 5.4834% of the total voting capital. Prior to this transaction, the fund held 5,749,083 shares, accounting for 4.9888% of the issued equity share capital.

Regulatory Disclosure Details

The disclosure was filed with the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirms that Kotak Mahindra Mutual Fund does not belong to the promoter or promoter group category.

The mode of acquisition was specified as open market purchases. The total equity share capital of Molbio Diagnostics remains unchanged at 11,52,39,996 equity shares of ₹1 each, both before and after the said acquisition.

Holding Structure Before and After Acquisition

What the Numbers Show

The acquisition marks a precise crossing of the regulatory reporting threshold. By acquiring exactly 0.4946% more than its previous 4.9888% holding, Kotak Mahindra Mutual Fund moved just above the 5.00% mark required for mandatory public disclosure. This suggests a strategic accumulation rather than a bulk block deal, given the relatively small percentage increase in a single transaction.

Molbio Diagnostics Limited witnessed a significant shareholding change as India Business Excellence Fund III disposed of 23,77,627 equity shares on September 30, 2026. This transaction represents a 2.06% reduction in the fund's total holding, executed through the open market.

The disposal triggered a disclosure requirement under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was submitted to both BSE and NSE by the fund's investment manager, MO Alternate Investment Advisors Private Limited.

Shareholding movement

Prior to this transaction, India Business Excellence Fund III held 1,02,76,750 shares, constituting 8.92% of the company's total voting capital. The sale of 23,77,627 shares has reduced the fund's stake to 78,99,123 shares, or 6.85% of the total diluted share capital.

Regulatory compliance and details

The disclosure confirms that the seller does not belong to the promoter or promoter group category. The transaction involved only equity shares carrying voting rights, with no involvement of warrants, convertible securities, or encumbered shares. The total equity share capital of Molbio Diagnostics remained unchanged at 11,52,39,996 equity shares of face value ₹1 each.

What the numbers show

The data reveals a concentrated exit strategy by a non-promoter institutional investor. By selling exactly enough shares to breach the 2% threshold in a single day, the fund reduced its exposure by nearly one-quarter of its previous position (from 8.92% to 6.85%). This significant drop in institutional backing may signal a shift in the fund's portfolio allocation or a reassessment of the company's near-term outlook, although no specific reasons for the sale were provided in the regulatory filing.